Royal Bank of Canada
CGTX icon

Royal Bank of Canada’s Cognition Therapeutics CGTX Stock Holding History

Royal Bank of Canada’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-400
Closed – – 7053
2025
Q1 		$0 Buy
+400
New +$235 ﹤0.01% 6853
2024
Q3 		– Sell
-338
Closed -$1K – 6910
2024
Q2 		$1K Buy
338
+334
+8,350% +$666 ﹤0.01% 6794
2024
Q1 		$0 Sell
4
-195
-98% -$403 ﹤0.01% 7058
2023
Q4 		$0 Buy
199
+176
+765% +$233 ﹤0.01% 7156
2023
Q3 		$0 Sell
23
-231
-91% -$362 ﹤0.01% 7123
2023
Q2 		$0 Buy
+254
New +$537 ﹤0.01% 7290
2023
Q1 		– Sell
-400
Closed -$1K – 7104
2022
Q4 		$1K Buy
400
+288
+257% +$582 ﹤0.01% 7011
2022
Q3 		$0 Buy
+112
New +$233 ﹤0.01% 7480
2022
Q1 		– Sell
-100
Closed -$1K – 7763
2021
Q4 		$1K Buy
+100
New +$975 ﹤0.01% 7487

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Royal Bank of Canada's CGTX Position: Q2 2025 in Review

Royal Bank of Canada sold out of Cognition Therapeutics (CGTX) in Q2 2025, closing a stake of 400 shares.

Royal Bank of Canada first reported a position in CGTX in Q4 2021 and held it in 9 quarters. The position peaked at $1K in Q2 2024. 48 funds tracked by Wall St. Rank hold CGTX as of Q2 2025.

  • Royal Bank of Canada reported no remaining Cognition Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 400 Cognition Therapeutics shares in Q2 2025.
  • Royal Bank of Canada first reported a position in Cognition Therapeutics in Q4 2021 and held it in 9 quarters.
  • Royal Bank of Canada's Cognition Therapeutics position peaked at $1K in Q2 2024.
  • 48 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2025.

Based on Royal Bank of Canada's 13F filing for Q2 2025, filed 14 Aug 2025.